MCID: ANP001
MIFTS: 60

Anaplastic Large Cell Lymphoma

Categories: Rare diseases, Immune diseases, Blood diseases, Cancer diseases

Aliases & Classifications for Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Anaplastic Large Cell Lymphoma:

Name: Anaplastic Large Cell Lymphoma 37 12 49 55 28 51 14
Alcl 49 55
Cd30 Positive Anaplastic Large Cell Lymphoma 55
Ki-1 Positive Anaplastic Large Cell Lymphoma 55
Ki-1+ Anaplastic Large Cell Lymphoma 69
Anaplastic Large-Cell Lymphoma 36
Primary Systemic Alcl 55
Sacl 55

Characteristics:

Orphanet epidemiological data:

55
anaplastic large cell lymphoma
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050744
Orphanet 55 ORPHA98841
MESH via Orphanet 42 D017728
UMLS via Orphanet 70 C0206180
ICD10 via Orphanet 33 C84.6 C84.7
KEGG 36 H01601
UMLS 69 C0206180

Summaries for Anaplastic Large Cell Lymphoma

Disease Ontology : 12 A non-Hodgkin lymphoma involving aberrant T-cells.

MalaCards based summary : Anaplastic Large Cell Lymphoma, also known as alcl, is related to primary cutaneous anaplastic large cell lymphoma and alk-positive anaplastic large cell lymphoma. An important gene associated with Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Adcetris and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 72 Anaplastic large-cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma involving aberrant T cells or... more...

Related Diseases for Anaplastic Large Cell Lymphoma

Diseases in the Anaplastic Large Cell Lymphoma family:

Anaplastic Small Cell Lymphoma

Diseases related to Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
# Related Disease Score Top Affiliating Genes
1 primary cutaneous anaplastic large cell lymphoma 33.5 ALK GZMB MUC1 NPM1 PTPRC
2 alk-positive anaplastic large cell lymphoma 33.5 ALK JAK3 MCL1 MUC1 NPM1 STAT3
3 lymphoma 31.7 ALK NPM1 PAX5 RNF213 TNFRSF8
4 lymphomatoid papulosis 31.3 ALK GZMB NPM1
5 inflammatory myofibroblastic tumor 30.7 ALK NPM1 RNF213
6 reticulosarcoma 30.7 ALK CLU GZMB MUC1 NPM1 PAX5
7 histiocytosis 30.5 CSF1R PTPRC TNFRSF8
8 diffuse large b-cell lymphoma 30.2 ALK PAX5 STAT3 TNFRSF8
9 mycosis fungoides 30.2 CLU GZMB STAT3 TNFRSF8
10 composite lymphoma 29.9 GZMB PAX5
11 myeloma, multiple 29.8 MCL1 PTPRC STAT3
12 combined immunodeficiency, x-linked 29.6 IL9 JAK3 PTPRC
13 severe combined immunodeficiency 29.4 IL9 JAK3 PTPRC
14 leukemia, acute myeloid 29.4 CSF1R MCL1 NPM1 PTPRC STAT3
15 lymphoma, hodgkin, classic 28.8 ALK GZMB PAX5 PTPRC TNFRSF8 TNFSF8
16 leukemia, chronic lymphocytic 28.6 MCL1 PAX5 PTPRC STAT3 TNFRSF8 TNFSF8
17 alk-negative anaplastic large cell lymphoma 12.6
18 anaplastic small cell lymphoma 11.6
19 eccrine porocarcinoma 10.4 MUC1 STAT3
20 autoimmune lymphoproliferative syndrome, type v 10.3
21 colon lymphoma 10.3 ALK PTPRC TNFRSF8
22 tenosynovial giant cell tumor 10.3 CLU CSF1R
23 conventional fibrosarcoma 10.3 PTPRC TNFRSF8
24 b-cell lymphomas 10.3
25 leukemia 10.3
26 reticulum cell sarcoma 10.3 MUC1 PTPRC TNFRSF8
27 malignant fibroxanthoma 10.2 ALK MUC1 PTPRC
28 malignant leydig cell tumor 10.2 PAX5 TNFRSF8
29 nodular lymphocyte predominant hodgkin lymphoma 10.2 PAX5 PTPRC
30 histiocytic and dendritic cell cancer 10.2 CLU PTPRC
31 peripheral t-cell lymphoma 10.2
32 testicular infarct 10.2 PTPRC TNFRSF8
33 adult lymphoma 10.2 ALK TNFRSF8
34 lymphatic system cancer 10.2 ALK NPM1 PTPRC TNFRSF8
35 hemophagocytic lymphohistiocytosis 10.2
36 lung lymphoma 10.1 GZMB PAX5 TNFRSF8
37 sarcoma 10.1
38 myeloid sarcoma 10.1 NPM1 PAX5 PTPRC
39 dermatitis 10.1
40 cerebritis 10.1
41 acute promyelocytic leukemia 10.0 CSF1R NPM1 PTPRC STAT3
42 hematologic cancer 10.0 ALK NPM1 PAX5 TNFRSF8
43 blood group, i system 10.0
44 adult t-cell leukemia 10.0
45 panniculitis 10.0
46 squamous cell carcinoma 10.0
47 t-cell leukemia 10.0
48 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.0
49 myeloid leukemia 10.0
50 soft tissue sarcoma 10.0

Graphical network of the top 20 diseases related to Anaplastic Large Cell Lymphoma:



Diseases related to Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Anaplastic Large Cell Lymphoma

GenomeRNAi Phenotypes related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CLU GZMB JUNB MCL1 TNFSF8 TRAF1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 CLU GZMB JUNB MCL1 TNFSF8 TRAF1

MGI Mouse Phenotypes related to Anaplastic Large Cell Lymphoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 STAT3 CSF1R TNFRSF8 IL9 TRAF1 JAK3
2 endocrine/exocrine gland MP:0005379 9.86 PTPRC RNF213 ALK STAT3 CSF1R TNFRSF8
3 immune system MP:0005387 9.77 STAT3 CLU CSF1R TNFRSF8 IL9 TNFSF8
4 neoplasm MP:0002006 9.1 ALK STAT3 JUNB NPM1 PAX5 PTPRC

Drugs & Therapeutics for Anaplastic Large Cell Lymphoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Adcetris 17 45 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011

Drugs for Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 391)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
4
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 23214-92-8 31703
5
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
6
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
7
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
10
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2 174722-31-7 10201696
11
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 2068-78-2, 57-22-7 5978
12
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
13
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
14
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
15
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
16
Mechlorethamine Approved, Investigational Phase 4,Phase 1,Phase 2 51-75-2 4033
17
Epirubicin Approved Phase 4 56420-45-2 41867
18
Crizotinib Approved Phase 4,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
21
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2 31703
22
Pirarubicin Investigational Phase 4 72496-41-4
23 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
26 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
30 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
31 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2
32 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
33 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
37 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
38 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
40 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
43 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
44 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
45 Hormones Phase 4,Phase 3,Phase 2,Phase 1
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1 0
49 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
50 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 351)

# Name Status NCT ID Phase Drugs
1 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
2 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
3 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Active, not recruiting NCT01909934 Phase 4 brentuximab vedotin
4 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
5 A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
6 Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma Unknown status NCT00006455 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;therapeutic hydrocortisone;vinblastine sulfate
7 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
8 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
9 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
10 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
11 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
12 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma Completed NCT00059839 Phase 3 doxorubicin hydrochloride;mercaptopurine;methotrexate;prednisone;vinblastine sulfate;vincristine sulfate
13 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
14 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
15 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
16 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
17 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
18 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
19 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
20 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
21 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
22 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
23 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
24 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
25 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
26 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
27 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
28 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
29 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
30 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
31 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma Completed NCT00003215 Phase 3 CHOP regimen;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;therapeutic hydrocortisone;vincristine sulfate
32 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Active, not recruiting NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
33 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Active, not recruiting NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate or Bexarotene
34 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
35 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
36 CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) Unknown status NCT02274584 Phase 1, Phase 2
37 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
38 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
39 Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse Unknown status NCT00069966 Phase 2 cisplatin;cytarabine;methylprednisolone;pixantrone dimaleate
40 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
41 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
42 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
43 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
44 Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma Completed NCT00079755 Phase 2 SGN-30 (anti-CD30 mAb)
45 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma Completed NCT00117988 Phase 2 tanespimycin
46 Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma Completed NCT00099255 Phase 2 SGN-30
47 A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Completed NCT00866047 Phase 2 brentuximab vedotin
48 Combination Chemotherapy in Treating Children With Lymphoma Completed NCT00002590 Phase 2 cyclophosphamide;cytarabine;daunorubicin hydrochloride;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate;pegaspargase;prednisone;thioguanine;vincristine sulfate
49 Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00278382 Phase 2 sorafenib tosylate
50 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;vincristine sulfate;pralatrexate

Search NIH Clinical Center for Anaplastic Large Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Anaplastic Large Cell Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Anaplastic Large Cell Lymphoma:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Anaplastic Large Cell Lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Anaplastic Large Cell Lymphoma

Genetic tests related to Anaplastic Large Cell Lymphoma:

# Genetic test Affiliating Genes
1 Anaplastic Large Cell Lymphoma 28

Anatomical Context for Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Anaplastic Large Cell Lymphoma:

38
T Cells, Breast, Bone, Bone Marrow, B Cells, Liver, Skin

Publications for Anaplastic Large Cell Lymphoma

Articles related to Anaplastic Large Cell Lymphoma:

(show top 50) (show all 1027)
# Title Authors Year
1
Response to "Why the Micromort Concept Falls Short in Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk Analysis". ( 29365059 )
2018
2
Prognostic factors of ALK-negative anaplastic large-cell lymphoma: a single-institution experience. ( 29359238 )
2018
3
Anaplastic Lymphoma Kinase Immunocytochemistry in Fine Needle Aspiration Diagnosis of Anaplastic Large-cell Lymphoma. ( 29403168 )
2018
4
Primary cutaneous anaplastic large-cell lymphoma: A case report. ( 29369180 )
2018
5
Anaplastic large cell lymphoma presenting as bilateral endobronchial tumor in a young boy. ( 29319039 )
2018
6
A 75-Year-Old Man with Progressive Generalized Erythroderma and History of Anaplastic Large Cell Lymphoma: Answer. ( 29286975 )
2018
7
Association of Breast Implants With Anaplastic Large-Cell Lymphoma. ( 29302678 )
2018
8
Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report. ( 29370815 )
2018
9
Case of primary cutaneous anaplastic large cell lymphoma misdiagnosed as squamous cell carcinoma by pseudocarcinomatous hyperplasia. ( 29314194 )
2018
10
Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma. ( 29030834 )
2018
11
Improvement of cutaneous anaplastic large cell lymphoma by brentuximab vedotin monotherapy. ( 29391331 )
2018
12
Why the Micromort Concept Falls Short in Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk Analysis. ( 29365043 )
2018
13
Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast. ( 29302687 )
2018
14
Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management. ( 29445921 )
2018
15
Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. ( 29026208 )
2018
16
Pseudogout Attack after Pegfilgrastim Administration in Anaplastic Large Cell Lymphoma. ( 29434148 )
2018
17
Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol. ( 29390984 )
2018
18
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. ( 28344319 )
2017
19
Composite lymphoma with coexistence of diffuse large B-cell lymphoma and anaplastic large cell lymphoma: Diagnostic pitfalls. ( 28631654 )
2017
20
Discussion: Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. ( 28953714 )
2017
21
EMMPRIN (CD147) is induced by C/EBPI^ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma. ( 28581487 )
2017
22
Reply: Breast implant associated anaplastic large cell lymphoma in Australia and New Zealand - high surface area textured implants are associated with increased risk. ( 28938349 )
2017
23
Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma. ( 28775121 )
2017
24
Bariatric Implant-Associated Anaplastic Large-Cell Lymphoma. ( 28945505 )
2017
25
Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma. ( 28370436 )
2017
26
Breast implant-associated anaplastic large cell lymphoma: A review and assessment of cutaneous manifestations. ( 28831423 )
2017
27
Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial. ( 28878445 )
2017
28
DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. ( 28522440 )
2017
29
Discussion: Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. ( 28953715 )
2017
30
Minimal Change Disease as Initial Presentation of ALK-Positive Anaplastic Large-Cell Lymphoma in a Pediatric Patient. ( 29279700 )
2017
31
Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma. ( 28414323 )
2017
32
Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma. ( 28665006 )
2017
33
Primary cutaneous anaplastic large cell lymphoma with intralymphatic involvement associated with chronic lymphedema. ( 28337783 )
2017
34
Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases. ( 29323068 )
2017
35
Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma. ( 28715445 )
2017
36
A case of CD30+ ALK1- anaplastic large cell lymphoma resembling acute disseminated encephalomyelitis. ( 28427693 )
2017
37
Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. ( 28153507 )
2017
38
ALK-Negative Anaplastic Large Cell Lymphoma Presenting as an Extranodal Soft-Tissue Mass With an Unusual Alveolar Growth Pattern: A Diagnostic Challenge. ( 28381153 )
2017
39
Primary gastrointestinal anaplastic large cell lymphoma. ( 28693749 )
2017
40
Re: Breast implant associated anaplastic large cell lymphoma in Australia and New Zealand - high surface area textured implants are associated with increased risk. ( 28938346 )
2017
41
Myxoid variant of primary cutaneous anaplastic large cell lymphoma: First 2 cases. ( 28626950 )
2017
42
Pyogenic variant of primary cutaneous CD30+ anaplastic large-cell lymphoma: Spontaneous remission in a young adult. ( 28834152 )
2017
43
Course of anti-ALK antibody titres during chemotherapy in children with anaplastic large cell lymphoma. ( 28857122 )
2017
44
ALK-positive anaplastic large cell lymphoma with soft tissue involvement in a young woman [Retraction]. ( 29296088 )
2017
45
Discussion: Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. ( 28953713 )
2017
46
Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile. ( 28975123 )
2017
47
Implications of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) for Breast Cancer Reconstruction: An Update for Surgical Oncologists. ( 28762113 )
2017
48
Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma. ( 29114604 )
2017
49
Primary cutaneous anaplastic large cell lymphoma. ( 28342276 )
2017
50
Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex. ( 27840423 )
2017

Variations for Anaplastic Large Cell Lymphoma

Copy number variations for Anaplastic Large Cell Lymphoma from CNVD:

7 (show all 11)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 19994 1 152394403 152431233 Translate TPM3 Anaplastic large cell lymphoma
2 122442 18 56200000 78077248 Loss Anaplastic large cell lymphoma
3 154895 20 49800000 58400000 Gain Anaplastic large cell lymphoma
4 154985 20 5100000 42100000 Gain Anaplastic large cell lymphoma
5 166394 3 101910849 101950501 Translate TFG Anaplastic large cell lymphoma
6 199890 5 4500000 23300000 Gain Anaplastic large cell lymphoma
7 264349 X 64804235 64878518 Translate MSN Anaplastic large cell lymphoma
8 300361 11 128069198 128187521 Translocation FLI1 Anaplastic large cell lymphoma
9 303153 2 29269143 29997936 Translocation ALK Anaplastic large cell lymphoma
10 303499 22 27994016 28026515 Translocation EWSR1 Anaplastic large cell lymphoma
11 304007 5 170747402 170770493 Translocation NPM1 Anaplastic large cell lymphoma

Expression for Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Anaplastic Large Cell Lymphoma.

Pathways for Anaplastic Large Cell Lymphoma

Pathways related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 CLU CSF1R IL9 JAK3 JUNB MCL1
2
Show member pathways
13.66 ALK CSF1R IL9 JAK3 JUNB MUC1
3
Show member pathways
13.18 ALK CSF1R IL9 JAK3 JUNB STAT3
4
Show member pathways
13.02 CSF1R IL9 JAK3 JUNB MCL1 MUC1
5 12.52 ALK CSF1R JAK3 STAT3 TFG TRAF1
6
Show member pathways
12.19 IL9 JAK3 MCL1 STAT3
7 12.09 CSF1R GZMB PAX5 TRAF1
8 11.74 GZMB JAK3 JUNB PAX5 PTPRC STAT3
9
Show member pathways
11.7 GZMB JAK3 STAT3
10
Show member pathways
11.67 JUNB MCL1 STAT3
11 11.63 GZMB IL9 PTPRC
12 11.61 CSF1R JAK3 PTPRC STAT3
13 11.41 JAK3 JUNB MCL1 MUC1 STAT3
14
Show member pathways
11.31 IL9 JAK3 STAT3
15
Show member pathways
11.28 CSF1R JAK3 STAT3
16 11.23 JAK3 PTPRC STAT3
17 11.18 PAX5 PTPRC STAT3 TNFRSF8
18 10.92 GZMB MCL1

GO Terms for Anaplastic Large Cell Lymphoma

Biological processes related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.97 ALK CSF1R NPM1 STAT3 TFG TNFRSF8
2 apoptotic process GO:0006915 9.88 CLU GZMB MCL1 TNFSF8 TRAF1
3 regulation of apoptotic process GO:0042981 9.73 ALK JAK3 MCL1 TRAF1
4 regulation of cell cycle GO:0051726 9.63 JUNB PTPRC STAT3
5 inflammatory response GO:0006954 9.55 CSF1R IL9 JAK3 STAT3 TNFRSF8
6 response to cytokine GO:0034097 9.43 JUNB MCL1 STAT3
7 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.4 JAK3 STAT3
8 interleukin-15-mediated signaling pathway GO:0035723 9.32 JAK3 STAT3
9 interleukin-9-mediated signaling pathway GO:0038113 8.96 IL9 JAK3
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 8.92 ALK CLU NPM1 TRAF1

Molecular functions related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.8 CSF1R JAK3 STAT3

Sources for Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....